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1. Introduction 
Cytogenetic methods are widely used during diagnosis in many types of hematological 
malignancies. Classical methods like karyotyping using GTG banding technique and 
molecular methods like fluorescent in situ hybridization (FISH) are still gold standard in 
clinics all over the world. According to WHO 2008 classification the cytogenetic analysis is 
the basic diagnostic tool during the diagnosis of blood neoplasms. Chromosomal 
abnormalities have established and known prognostic significance. According to the 
European Leukemia Net-Workpackage Cytogenetics – the cytogenetic diagnostic is essential 
for disease classification, prognostic assessment and treatment decisions. Despite the fact 
that new molecular methods  are very promising the classical cytogenetic methods together 
with FISH are still the reference test in many hematological neoplasms. 
2. Cytogenetic techniques 
Cytogenetic techniques are the basis in hematological diagnostics. From the first described 
chromosomal aberration characteristic for CML- Philadelphia chromosome by Nowel and 
Hungeford in 1960 it appeared that almost every hematological neoplasm possess typical 
changes in karyotype.  
Bone marrow is the most suitable material for cytogenetic diagnostics in hematological 
malignancies. The most important principle is to aspirate the bone marrow in sterile way to 
heparin filled probes. Then the procedure of in vitro culture and preparing microscopic 
slides with metaphase chromosomes and/or interphase nuclei is started. 
2.1 Classical cytogenetics 
Chromosomes in metaphase are indispensable for karyotyping. For this purpose aspirated 
bone marrow cells are cultured in vitro. Preliminary preparation comprise the lysis in NH4Cl 
solution to obtain mononuclear cells, which are then counted. These two important steps 
www.intechopen.com
 
Recent Trends in Cytogenetic Studies – Methodologies and Applications 58
have a serious influence on further results on in vitro culture and finally on chromosome 
quality. Counted cells are placed in the medium with fetal bovine serum and appropriate 
growth factor. Non stimulated cells should be also parallel culture. Usually the culture  
takes 24 hours, but if the number of cells is sufficient, additional cultures for 48 hours or 
even 72 hours should be made. The most suitable for authentic diagnostics  is 24-hours 
culture without any stimulating factor (only medium and serum). 
In hematological patients especially pediatric, the aspiration of bone marrow could be 
problematic. Sometimes the quality of aspirated bone marrow is very poor, so it is very 
important in such cases to put more carefulness and attention during procedures of culture. 
After 23 hours of culture the cell cycle is stopped by incubation for 1 hour with colcemid 
solution which blocked the cells in metaphase. Then the procedure of hypotonic shock with 
KCl and Carnoy’s fixation is begun to obtain chromosomes slides which are ready for 
banding techniques- the most common in the world- GTG banding using Giemsa stain and 
trypsin. Analysis is conducted using high quality microscope with special karyotyping 
software by experienced cytogenetists. The karyotype analysis covers the counting of the 
patient’s chromosomes and structure study of each pair to detect any aberrations. The 
changes in the karyotype are described using international nomenclature with comments 
about eventually significance on prognosis. 
2.2 Fluorescent in situ hybridization 
The most important principle during preparation of slides for fluorescent in situ 
hybridization (FISH) is to obtain interphase nuclei from non-cultured and non-stimulated 
cells immediately after aspiration of material. Further differences between percentage of 
neoplasm cells in FISH analysis and in karyotype, result from fact that FISH technique is 
conducted on fresh material and karyotype after in vitro culture. So FISH represents the state 
of patient at the time of bone marrow aspiration. It could be possible that cells with 
aberration visualized by FISH are not detectable in karyotype. To obtain appropriate slides 
for FISH, cells after lysis, are incubated with KCl and fixated with methanol and glacial 
acetic acid. 
Nowadays there is a wide spectrum of accessible commercial FISH probes ready for use 
created for almost every described chromosomal aberration observed in hematological 
malignancies. These commercial probes included translocation probe, deletion probe, 
centromeres, telomeres, painting probes (whole or only some fragments of 
chromosomes) available in many colors depending on possessed fluorescence filters in 
microscope.  
3. Hematological malignancies 
Hematological malignancies are a group of neoplasms derived from malignant transformed 
bone marrow cells. These types of cancers affect the peripheral blood, bone marrow, liver, 
spleen and lymph nodes. The great diversity in this group of disorders is due to the 
complexity in hematopoiesis and immunological system. Many classifications were created 
but the last most accepted is the World Health Organization (WHO) classification (2008) 
made by many hematologists from all over the world. The primary basis of this 
classification is the distinction of the origin of tumor cells: lymphocytes or myeloid cells. 
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Since chromosomal aberrations are common cause in the hematological malignancies and 
hence it is necessary to use the cytogenetic methods during the diagnosis and treatment 
evaluation. 
3.1 CML – Chronic myeloid leukemia 
Chronic myeloid leukemia (CML) is a clonal bone marrow stem cell disorder in which 
proliferation of mature granulocytes and their precursors is increased. The BCR/ABL fusion 
resulting from translocation t(9;22) is the well-known pathogenic key of this disease. The 
standard analysis during diagnosis cover the karyotype, FISH and molecular establishment 
of the type and the level of transcripts. Using the cytogenetic methods is very important 
during recognition of CML.  
Usually in CML patient we can observe in the karyotype the translocation t(9;22) resulting  
as chromosome Philadelphia. About 1% cases of CML have so called masked chromosome 
Philadelphia (Virgili et al., 2008). Then in karyotype there is a normal structure of 
chromosomes (Fig. 1). In such cases it is obligatory to perform the FISH analysis to visualize 
the fusion of ABL and BCR genes (Fig. 2).  
 
 
 
Fig. 1. CML patient with masked Philadelphia chromosome. Normal GTG banding 
karyotype shows no abnormalities between chromosomes 9 and 22. 
Apart from classical translocation t(9;22) in karyotype we can observe different secondary 
aberrations. We had a patient with three aberrations in the karyotype during blast crisis: 
t(9;22) with BCR/ABL fusion, t(3;21) with EVI/AML1 fusion and an inversion of 
chromosome 2. Knowledge of the importance of specific translocations, like t(3;21), can help  
clinicians. Our patient had no hematological and clinical sings of relapse, but appearance of 
t(3;21) translocation indicates the clinicians about the upcoming progression of the disease 
(Kim et a., 2009). It could not be possible to detect this changes using only FISH method or 
RT-PCR. Only karyotype could reveal all the three aberrations. (Fig.3). 
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Fig. 2. CML patient with masked Philadelphia chromosome. FISH analysis revealed the 
fusion between BCR and ABL genes on chromosome 22. The probe BCR/ABL dual color, 
dual fusion- red signals seen on chromosome 9q34, green- on chromosome 22q11.2.  
 
Fig. 3. Karyotype of patient with CML revealed three aberrations: t(9;22)(q34;q11), 
t(3;21)(q26;q22) and inversion of chromosome 2. 
3.2 AML – Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a clonal disorder characterized by various genetic 
abnormalities and variable response to the treatment. In AML, cytogenetic methods are used 
to stratify patients to three different risk groups: good, intermediate and poor (Akagi et al, 
2009). Karyotype feature in the favorable risk group include t(8;21), t(15;17) and 
www.intechopen.com
 
Cytogenetics in Hematooncology 61 
inv(16)/t(16;16). In the intermediate risk group characteristic feature of karyotype are: 
normal karyotype, -Y, del7q, del9q, t(9;11), del11q, isolated trisomy 8, +11,+13,+21, del20q. 
Aberrations with adverse prognosis are: complex karyotype, inv(3)/t(3;3), monosomy 5, 7, 
t(6;9), t(6;11), t(11;19). Unfortunately about 40-50% of AML cases represent normal 
karyotype with intermediate prognosis (Rausei-Mills et al, 2008). Due to this fact additional 
molecular genetic investigations are of increasing importance during each new diagnosed 
AML case.  
For patients with de novo AML the best clinical approach is the classical cytogenetic analysis 
including FISH technique to categorize patients into specific risk group. In AML patients 
with normal karyotype it is strongly recommended to examine molecular background of the 
disease -detection of mutations in genes such as FLT3, NPM1 or CEBPA (Döhner et al, 2008). 
Although translocation t(15;17) with fusion of PML/RARα genes characteristic for acute 
promyelocytic leukemia (APL) has established good prognosis, in some cases it could not be 
so easy to interpret. In our laboratory there was a patient (2-years-old boy) with diagnosed 
AML-M3. FISH analysis revealed single fusion of PML/RARα genes (Fig.4), with three 
signals from PML gene (green), and two from RARα gene (red). Karyotype was very 
difficult to analyze, and many FISH procedures with different probes were needed to 
established at least very complex karyotype with PML/RARα fusion gene on derivative 
chromosome 16 (Fig. 5). ISCN record of karyotype showed as follow:  
46,XY,der(4)(4pter→4q26::16q22→16qter),der(15)(15pter→15q23::4q31.3→4qter),der(16)(16q
22→16p11.2::17q25→17q21::4q26→4q31.3::17q21::15q23→15qter),der(17)(17pter→17q21::16p
11.2→16pter) [20] 
Schematic representation (Fig.6) indicates possible way of process of occurrence of 
aberrations. Red color represents the chromosome 4, blue- 15, green- 16 and grey- 17. The 
fusion of PML/RARα genes on derivative chromosome 16 was also indicated. So complex 
karyotype  shows rather poor prognosis in this patient. 
 
 
 
Fig. 4. FISH with PML/RARα probe revealed single fusion (indicated by arrow). 
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Fig. 5. Karyotype of APL patient with complex rearrangements involving chromosomes 
4,15,16 and 17. 
 
Fig. 6. Schematic representation of complex aberrations involving chromosome 4,15,16 and 
17 in the karyotype of APL patient. 
3.3 ALL – Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most often childhood neoplasm account about 
30% of all cancer. Frequency of ALL depends on the age and in children estimates about 
85% acute leukemias, while in adults only about 20%. The highest morbidity in children 
concern age between 2 and 6 (Deangelo, 2005). ALL is a heterogeneous group of leukemias 
which can differ between patients depending on age. The characteristic feature is 
accumulation of  immature lymphoblasts in the bone marrow, peripheral blood and lymph 
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nodes (Hamouda et al., 2007). Now a huge progress in treatment results and long-term 
remission is noted in children with ALL. About  80% of patients achieved complete 
remission and 5-year event free survival (Brassesco et al., 2011). Despite these facts relapses 
are still the main reason of treatment failure. 
The most important step during diagnosis of ALL is the assessment of biological and genetic 
features of lymphoblasts (Tucci and Arico, 2008). Usually the prognostic factors are: gender, 
age, WBC, cytogenetic and immunophenotypic features of bone marrow cells, steroid 
resistance and time of remission achievement. Based on these factors the risk groups are 
determined as: standard, intermediate and high (Boer et al., 2009). 
The most frequent (25% children’s ALL) chromosomal aberrations with good prognosis are 
translocation t(12;21) with ETV6/RUNX1 genes fusion and hiperdiploidy more than 50 
chromosomes. From poor prognostic cytogenetic factors the translocation t(9;22), MLL 
rearrangements and hypodiploidy under 45 chromosomes are listed. Normal karyotype has 
the intermediate prognosis (Harrison et al., 2010). Characteristic features for ALL blast cells 
show short time survival and low proliferation ratio, so it is relatively often (about 16% of 
ALL cases), it is impossible to obtain metaphases and established karyotype (Heng et al., 
2010). 
We presented here the very rare aberration typical for B-ALL- the dicentric chromosome 
dic(9;20). After GTG banding (Fig. 7) this chromosome form was recognizable, but 
additional FISH with whole chromosome probes resolved the deletion or additional 
aberrations of chromosome 20 arm p (Fig. 8.). Median age for patients  with this aberration 
is 3 years, and it more frequently occurred in girls. ALL patients with dic(9;20) responded 
well for initial therapy, but  relapses are detected relatively often. 
 
 
 
Fig. 7. The karyotype 45,XX,dic(9;20)(p13;q11),del(17)(q23),-20 of patient with ALL 
presenting the dicentric chromosome between chromosome 9 and 20. 
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Fig. 8. FISH with whole chromosome probes for chromosome 9 (WCP 9 red) and 20 (WCP 20 
green) in ALL patient with dicentric chromosome dic(9;20). 
3.4 MDS – Myelodysplastic syndrome 
Myelodysplastic syndromes are a heterogeneous group of clonal disorder of pluripotent 
hematopoietic stem cells which are characterized by ineffective hematopoiesis, peripheral 
blood cytopenia and fibrosis in the bone marrow. MDS often evolve to acute myeloid 
leukemia. Cytogenetic aberrations described in MDS patients, are common in AML as well 
(Vardiman et al., 2009). Myelodysplastic syndrome can be primary and secondary (therapy 
related) disorder. The most common difficulty in laboratory work with material from 
patients with MDS is cytopenia. It means, that there is very few cells obtained from 
clinicians to analyze. So careful proceeding with such a material, not to waste any cell, is the 
most important key. 
We presented here one case of primary MDS with unbalanced recurring chromosomal 
abnormality isodicentric of chromosome X- idic(X)(q13) (fot.9) and one patient with therapy-
related MDS with balanced translocation t(2;3) and monosomy 7 (fot.10,11). 
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Fig. 9. Karyotype of female with primary MDS with characteristic double centromere in one 
of chromosome X - 46,XX,idic(X)(q13). 
 
 
 
 
Fig. 10. Karyotype of patient with secondary MDS with balanced translocation between 
chromosomes 2 and 3 and monosomy 7- 45,XY,t(2;3)(p15;q27),-7. 
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Fig. 11. FISH confirming the balanced translocation t(2;3)(p15;q27) in patient with secondary 
MDS. 
3.5 CLL – Chronic lymphocytic leukemia 
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western 
world and primarily affects the adults. CLL is characterized by accumulation of 
immunologically incompetent B lymphocytes in the bone marrow, blood and lymphoid 
organs (Hodgson et al., 2011). CLL is a biologically heterogeneous illness, that in some 
patients has an indolent feature that not require any therapy, while in others run with 
aggressive leukemia, which need immediate treatment (Bryan and Borthakur, 2010). 
Almost 80% patients with CLL have acquired chromosomal abnormalities. The most 
frequent is deletion 13q (55% of patients) with rather good prognosis. Deletion 11q, 
especially deletion of ATM gene is found in 18% of CLL patients and is associated with 
adverse prognosis. Trisomy of chromosome 12 and normal karyotype (16-18%) have no 
established risk prognosis, while deletion 17p (found in 7% of individuals) related with 
deletion of p53 gene has the worse prognosis and highest risk of the treatment failure 
(Döhner et al., 2000). 
We presented here simple examples of non-deleted and deleted interphase nuclei from CLL 
patients after FISH technique (Fig.12 a,b). CLL is the only hematological disorder, in which 
reference material for cytogenetic analysis can be peripheral blood. Bone marrow aspiration  
from CLL patients is very rare, and usually the standard proceeding, including FISH 
analysis with 4 probes specific for deletion  13q14, ATM gene, p53 gene, and trisomy 12.  
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Fig. 12. a) FISH with p53 probe in patient presenting deletion of p53 gene (one red signal 
from p53 gene, two green signals from centromere of chromosome 17) (b). FISH with p53 
probe on interphase nuclei of patient with CLL- no deletion of p53 gene was detected (with 
two red and two green signals). 
Sometimes CLL patients  examined only with FISH technique can be misled by the 
clinicians. We had an individual with known deletion 13q14 (rather good prognosis), while 
karyotype revealed an additional aberration - translocation t(7;14)(p15;q11),which is rather  
rarely observed, but characteristic for T-ALL (Fig. 13). This abnormality in CLL patient 
could indicate on possible progression toward acute lymphoblastic leukemia.  
 
 
 
Fig. 13. CLL patient with deletion of 13q14 region (invisible in GTG banding- detected by 
FISH) and translocation between chromosomes 7 and 14- characteristic for T-ALL. 
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3.6 MPN – Myeloproliferative neoplasms 
Myeloproliferative neoplasms are characterized by proliferation of multipotent stem blood 
cell. According to WHO (2008) these neoplasms can be divided into eight disorders not 
taking into account the presence the BCR/ABL transcript (Vannucchi et al., 2009). Except the 
chronic myeloid leukemia, all other myeloproliferative neoplasms are negative for 
BCR/ABL transcript, but the common feature is the frequent presence of JAK2 mutation. 
Myeloproliferative neoplasms are characterized by increased proliferation of one up to three 
hematopoietic cell lineages in the bone marrow, what has the great impact on peripheral 
blood parameters.  
At present, after exclusion of CML, all patients are tested toward the JAK2 mutation and 
eventually in the direction of  any other  changes in karyotype. Cytogenetic aberrations are 
rather uncommon in MPN. In our laboratory however, there were few cases with specific 
and interesting changes in karyotype. Important thing to remember while working with 
material form MPN patients is accurate counting of mononuclear cells. Too large number of 
cells in the in vitro culture may result in failure to obtain the chromosome metaphase. 
We present patient with MPN, which was positive for the JAK2 V617F mutation and has a 
duplication in the long arm of chromosome 1- a rare aberration in this type of hematological 
disorder (Fig. 14). 
 
 
 
Fig. 14. MPN patient with duplication in the long arm of chromosome 1 - 
46,XX,dup(1)(q21q32). 
4. Conclusion 
Acquired chromosomal aberrations are the leading molecular cause  in the development of 
neoplasms. Deletions, translocations, amplifications which are clonal changes in karyotype 
can be detected in most of hematological disorders. Cytogenetic techniques like GTG 
karyotyping and FISH are excellent to reveal these aberrations. Also molecular techniques 
suitable for detection of mutations and quantitative measurement of known pathogenic 
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transcripts have great importance. In molecular diagnostics of hematological malignancies 
in XXI century there is a great need to connect cytogenetic and molecular techniques. In our 
laboratory parallel GTG karyotype, FISH and molecular methods are carried out for 
diagnosis of hematological patients. 
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